Why Enanta Pharmaceuticals, Inc. Should Be on Your Watchlist

Enanta Pharmaceuticals and its collaborator AbbVie are inching closer to a regulatory filing for their hepatitis C drug. Here is what you need to know heading into this event.

Apr 9, 2014 at 9:30AM

The next-generation hepatitis C drug race is rapidly coming to a head with Gilead Sciences' (NASDAQ:GILD) regulatory filing of its all-oral, once-daily combo pill of Sovaldi plus ledipasvir and the anticipated filing of a New Drug Application for AbbVie (NYSE:ABBV) and Enanta Pharmaceuticals(NASDAQ:ENTA) competing hepatitis C regimen later this year. With these so-called "terminator" hepatitis C therapies likely to compete in the near future, investors have been focusing on whether AbbVie or Gilead offers the more compelling risk-to-reward ratio going forward. As a result, Enanta Pharmaceuticals has sort of gotten lost in the shadows of these pharma giants, evidenced by the company's mere $600 million market cap. That said, I believe there are three compelling reasons why Enanta Pharmaceuticals could offer the best investing vehicle to gain exposure to these game-changing hepatitis C drugs. 

Reason No. 1
Per Enanta's recent 10-Q, AbbVie plans to file an NDA for the duo's triple-therapy hepatitis C regimen in the second quarter of this year, with the goal of launching the drug before year's end. The filing will be based on the results of six late-stage studies showing that this therapy is essentially a functional cure for some forms of hepatitis C, even among patients that previously failed to respond to other therapies. What's important to bear in mind from an investing standpoint is the agreement between AbbVie and Enanta. Going forward, Enanta is owed up to $195 million in milestone payments, many of which could be triggered by a successful NDA filing. That's a nice chunk of change for a company sporting a market cap under $700 million. Even so, Enanta is also eligible for royalty payments that range from low double digits up to 20% of sales. In sum, Enanta will be earning a fairly significant amount of revenue through this agreement soon, although the exact numbers will only be clear later as this process unfolds.

Reason No. 2
AbbVie is responsible for bearing the significant costs of the regulatory filing and commercialization of the therapy. One of the most disappointing aspects of investing in clinical-stage biotechs is that investor enthusiasm following a successful regulatory filing can quickly be rendered moot by the harsh realities of commercializing a drug. Put simply, most development biotechs lack the significant resources needed to launch new drugs without substantial dilution to shareholders. Enanta shareholders can rest easy, however, because AbbVie is solely responsible for this portion of the therapy's life cycle. Enanta can thus focus its resources on the development of other compounds in its pipeline, creating further value for shareholders.

Reason No. 3
I expect the competition between AbbVie and Gilead in the hepatitis C space to be fierce. Each company has invested tremendous resources into their respective drugs and the hepatitis C market may not be sustainable over the long term. Specifically, the chronic hepatitis C market has naturally been declining in the U.S. for decades, and these new functional cures could hasten the disease's decline. AbbVie, Gilead, and other drugmakers will therefore likely be forced to rely more heavily upon ex-U.S. markets for hepatitis C sales, where prices are often dramatically lower. Gilead has reportedly already discounted Sovaldi by 99% in Egypt due to the prevailing socioeconomic problems in the country, combined with its world-leading rate of hepatitis C infections.

Again, Enanta does not have to worry about the complexities of the hepatitis C market for the most part, as the agreement with AbbVie entitles it to substantial up-front payments. And by the time the hepatitis C market has started to wane in the U.S., Enanta will probably have shifted its focus to other experimental compounds such as its antibiotics for MRSA. 

Foolish wrap-up
There are always two sides to an investing thesis, namely risk and reward. Although AbbVie and Gilead are widely expected to see blockbuster sales for their respective hepatitis C drugs, Enanta looks like it may be a better investing vehicle than either company because it faces fewer downside risks due to its agreement with AbbVie. Moreover, the milestone and royalty payments expected under the agreement are considerable in light of Enanta's current market cap. You can't exactly say the same for the projected sales of either AbbVie's or Gilead's drugs compared to their market cap. So, you may want to dig deeper into Enanta heading into the regulatory filing of its experimental hepatitis C therapy. 

Three stocks to own for the rest of your life
As every savvy investor knows, Warren Buffett didn't make billions by betting on half-baked stocks. He isolated his best few ideas, bet big, and rode them to riches, hardly ever selling. You deserve the same. That's why our CEO, legendary investor Tom Gardner, has permitted us to reveal "The Motley Fool's 3 Stocks to Own Forever." These picks are free today! Just click here now to uncover the three companies we love. 

George Budwell owns shares of Gilead Sciences. The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers